Introduction
Ovarian cancer carcinogenesis and progression: molecular mechanisms
Anti-cancer effects of quercetin
Quercetin and ovarian cancer
Form of quercetin | Doses | Type of cervical cancer | Model | Findings | Ref |
---|---|---|---|---|---|
Quercerin | 80 mg/kg twice a week | – | In vivo | Induced apoptosis, induced ER stress, activated p-STAT3/ Bcl2 axis, induced protective authophagy, | [78] |
34′7TMQ | – | Epithelial and fibroblast ovarian cancer cell lines | In vitro | Inhibited cell migration and invasion, inhibited expression of uPA and MMP-2 | [90] |
Quercetin | A dose range | Metastatic ovarian cancer cell line | In vitro | Decreased viability, induced apoptosis, decreased Bcl-2 and Bcl-xL, increased caspase-3, caspase-p, Bid, Bad, Bax, cytochrome c | [79] |
Quercetin | 100 μM | Multi-drug resistant ovarian cancer cell line | In vitro | Increased ER stress, prolonged DNA repair, increased expression of p53, p21 and Bax, decreased expression of Bcl-2, induced radio-sensitization, | [81] |
Quercetin | – | Human ovarian cancer xenograft model | In vivo | increased radiation-induced cell death, increased p53, increased ER stress | |
Quercetin | A dose range | Cisplatin sensitive and resistant cell lines | In vitro | Enhanced cisplatin cytotoxicity, increased ER stress, suppressed STAT-3 phosphorylation, decreased expression of Bcl-2, | [82] |
40 mg/kg once a week | Human ovarian cancer xenograft model | In vivo | Suppressed STAY-3 phosphorylation, decreased Bcl-2 expression, induced apoptosis | ||
Quercetin | A dose range | Epithelial ovarian cancer cell line and its CIS-resistant cell line | In vitro | Decreased expression of cyclin D1 | [85] |
Quercetin | A dose range | Epithelial ovarian cancer cell line | In vitro | Inhibited proliferation, induced apoptosis, decreased survivin, induced cell cycle arrest | [86] |
Nano-formulation of quercetin | A dose range | Ovarian endometrioid adenocarcinoma | In vitro | Inhibited growth, induced apoptosis, activated caspase-3 and caspase-9, decreased expression of MCL-1 and Bcl-2, increased expression of Bax | [80] |
A dose range | Human ovarian cancer xenograft model | In vivo | Inhibited growth, induced apoptosis, inhibited angiogenesis | ||
Quercetin | A dose range | Epithelial and drug resistant ovarian cancer cell lines | In vitro | Decreased ROS, increased anti-oxidant enzymes, inhibited apoptosis | [91] |
Human ovarian cancer xenograft model | In vivo | Increased anti-oxidant enzymes expression, reduced ROS, decreased anti-neoplastic drug’s efficacy | |||
Lipo-Que | – | CIS-resistant and CIS-sensitive ovarian cancer cell lines | In vitro | Inhibited proliferation, induced apoptosis, induced cell cycle arrest | [83] |
Human ovarian cancer xenograft model | In vivo | Inhibited tumor growth, inhibited proliferation, induced apoptosis | |||
Quercetin | 2 mg / kg | Human ovarian cancer xenograft model | In vivo | Increased TRAIL sensitization, inhibited tumor growth, increased caspase-3, induced apoptosis | [88] |
Quercetin | 10 microM | Ovarian serous adenocarcinoma | In vitro | Increased TGF beta 1 activity | [89] |
Quercetin | A dose range | Metastatic ovarian serous adenocarcinoma | In vitro | Inhibited PI kinase, decreased IP3 levels | [87] |